文献速递哮喘

哮喘患者过度使用短效β2受体激动剂与急性加重及死亡风险增加相关:全球SABINA项目全国队列研究

Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme.
PubMed 文献 · Eur Respir J · 2020-04-16

30%患者过度使用短效β2受体激动剂(SABA,每年收集>2罐),SABA使用罐数增加与急性加重和死亡风险呈递增关联。

要点

  • 30%哮喘患者过度使用SABA(每年>2罐),其中21%为3-5罐/年、7%为6-10罐/年、2%为≥11罐/年。
  • SABA使用罐数增加与急性加重风险递增相关,≥11罐/年HR达1.77(95%CI 1.72-1.83)。
  • SABA使用罐数增加与死亡风险递增相关,≥11罐/年HR达2.35(95%CI 2.02-2.72)。

核心结论

  • 瑞典约三分之一哮喘患者每年收集3罐及以上SABA,SABA过度使用与急性加重和死亡风险增加相关。
  • 监测SABA使用应成为改善哮喘管理的关键环节。

主要发现

  • 30%患者过度使用SABA,21%每年收集3-5罐、7%收集6-10罐、2%收集≥11罐。
  • 与每年≤2罐相比,SABA收集3-5罐的急性加重HR为1.26(95%CI 1.24-1.28),6-10罐为1.44(95%CI 1.41-1.46),≥11罐为1.77(95%CI 1.72-1.83)。
  • 与每年≤2罐相比,SABA收集3-5罐的死亡HR为1.26(95%CI 1.14-1.39),6-10罐为1.67(95%CI 1.49-1.87),≥11罐为2.35(95%CI 2.02-2.72),共观察2564例死亡。

关键数值与推荐

  • SABA过度使用定义为纳入后1年基线期内收集超过2罐SABA。
  • SABA使用按基线年收集罐数分为3-5罐、6-10罐和≥11罐组。
  • 急性加重定义为住院和/或口服糖皮质激素索赔。

临床怎么用

  • 对哮喘患者应常规监测SABA处方/收集数量,每年超过2罐提示控制不佳并需评估。
  • SABA过度使用(尤其是每年≥11罐)应视为急性加重和死亡高风险信号,需强化抗炎治疗与随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Overuse of short-acting β2-agonists (SABA) may indicate poor asthma control and adverse health outcomes. Contemporary population-based data on use, risk factors and impact of SABA (over)use on asthma exacerbations and mortality are scarce, prompting initiation of the global SABINA (SABA use IN Asthma) programme. METHODS: By linking data from Swedish national registries, asthma patients aged 12-45 years with two or more collections of drugs for obstructive lung disease during 2006-2014 were included. SABA overuse was defined as collection of more than two SABA canisters in a 1-year baseline period following inclusion. SABA use was grouped into 3-5, 6-10 and ≥11 canisters per baseline-year. Cox regression was used to examine associations between SABA use and exacerbation (hospitalisations and/or oral corticosteroid claims) and mortality. RESULTS: The analysis included 365 324 asthma patients (mean age 27.6 years; 55% female); average follow-up was 85.4 months. 30% overused SABA, with 21% collecting 3-5 canisters per year, 7% collecting 6-10 canisters per year and 2% collecting ≥11 canisters per year. Increasing number of collected SABA canisters was associated with increased risk of exacerbation, as follows. 3-5 canisters: hazard ratio (HR) 1.26 (95% CI 1.24-1.28); 6-10 canisters: 1.44 (1.41-1.46); and ≥11 canisters: 1.77 (1.72-1.83), compared to two or fewer canisters per year. Higher SABA use was associated with incrementally increased mortality risk (2564 deaths observed), as follows. 3-5 canisters: HR 1.26 (95% CI 1.14-1.39); 6-10 canisters 1.67 (1.49-1.87); and ≥11 canisters: 2.35 (2.02-2.72) compared to two or fewer canisters per year. CONCLUSION: One-third of asthma patients in Sweden collected three or more SABA canisters annually. SABA overuse was associated with increased risks of exacerbation and mortality. These findings emphasise that monitoring of SABA usage should be key in improving asthma management.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Nwaru BI, Ekström M, Hasvold P, et al. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur Respir J. 2020. PMID: 31949111. doi:10.1183/13993003.01872-2019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。